Zenas BioPharma Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Provided By GlobeNewswire
Last update: Nov 12, 2025
- Obexelimab Phase 3 INDIGO trial topline results in Immunoglobulin G4-Related Disease (IgG4-RD) expected around year-end 2025 -
- Reported highly positive 12-week primary endpoint results from Phase 2 MoonStone trial of obexelimab in Relapsing MS (RMS) -
Read more at globenewswire.com
